Business Context and Reporting Period
This Form 8-K Current Report was filed by Inmune Bio, Inc. on January 24, 2022. The report addresses Item 8.01 (Other Events) regarding the termination of Rule 10b5-1 trading plans by three senior executives.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on executive trading plan terminations and does not contain financial performance data.
Material Changes
The material event reported is the termination of previously established 10b5-1 trading plans by the following executives, with the number of shares sold under each plan noted:
- David J. Moss (CFO): Terminated plan on January 26, 2022. 29,259 shares sold pursuant to the plan.
- Raymond J. Tesi (CEO): Terminated plan on January 24, 2022. 63,759 shares sold pursuant to the plan.
- Mark Lowdell (CSO): Terminated plan on January 25, 2022. 33,458 shares sold pursuant to the plan.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary on operations, risks, contingencies, or unusual items. The document is limited to the disclosure of the trading plan terminations.
Investor Verification Checklist
- Verify the total number of shares sold by executives under terminated 10b5-1 plans (Total: 126,476 shares).
- Confirm the specific termination dates for each executive's trading plan (January 24, 25, and 26, 2022).
- Review the original 8-K filed on March 16, 2021, for the initial terms of these trading plans.